Screener
Taysha Gene Therapies, Inc. TSHA Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of term loan | (1,470) | (1,530) |
| Interest income | 2,586 | 1,326 |
| Interest expense | (9) | (19) |
| Other income (expense) | (31) | 13 |
| Total other income (expense), net | 1,076 | (108) |
| Net loss | $(42,410) | $(21,529) |
| Net loss per common share, basic and diluted | $(0.12) | $(0.08) |
| Weighted average common shares outstanding, basic and diluted | 366,632,827 | 269,306,331 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s other income (expense)?
- Taysha Gene Therapies, Inc. (TSHA) reported other income (expense) of $1.08M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s other income (expense) changed year-over-year?
- Taysha Gene Therapies, Inc.'s other income (expense) increased by 1096.3% year-over-year, from -$108K to $1.08M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s other income (expense)?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s other income (expense) has grown at a 6.2% compound annual growth rate (CAGR), from -$1.26M to $1.5M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Taysha Gene Therapies, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude